Laigo Bio, a Utrecht-based BioTech agency targeted on protein degradation for focused therapies, has concluded the second shut of its Seed funding spherical, elevating an additional €5.5 million, bringing the entire quantity raised to €17 million.
The €5.5 million raised contains further funding of €4 million secured from new co-lead investor Biovance Capital and €1.5 million from present co-lead Kurma Companions. With this funding, Dr João Incio, Basic Accomplice at Biovance Capital, will be part of Laigo’s board of administrators. Laigo Bio completed the preliminary shut of its Seed financing spherical at €11.5 million in December 2025.
“The second shut of our seed financing spherical additional validates the potential of our SureTACs platform and its means to determine first-in-class twin focused therapies to redefine the remedy of most cancers and autoimmune illnesses. The extra funding and help from new co-lead investor Biovance Capital, alongside additional funding from our present co-lead investor Kurma Companions, will speed up our oncology applications in the direction of the clinic and improve our discovery efforts in auto-immunity and immunology. We welcome Dr João Incio to the Board of Administrators,” stated Dr Matthew Baker, Chief Govt Officer of Laigo Bio.
Laigo Bio was based by the Oncode Institute, along with the Oncode Bridge Fund, and Argobio Studio, a French BioTech startup studio launched by Kurma Companions, BPI France and Angelini Ventures, key gamers in financing innovation in healthcare.
Argobio Studio was launched in 2021 with €50 million of dedicated capital to create and develop progressive BioTech spinouts, specializing in particular therapeutic areas resembling uncommon illnesses, neurological problems, oncology, and immunology.
Laigo Bio used E3 ligase-induced internalisation and selective degradation of membrane-bound targets concerned in autoimmune and inflammatory illnesses. The corporate has devised a novel expertise (SureTACs) that facilitates the exact removing of proteins situated on any cell floor.
SureTACs, developed in collaboration with Prof Madelon Maurice’s laboratory on the UMC Utrecht and the Oncode Institute, are proprietary therapeutic candidates for the focused degradation of membrane proteins which were validated as illness drivers however have beforehand eluded drug discovery and had been lengthy thought-about “undruggable”.
SureTACs are bispecific antibody molecules that induce degradation by bringing the cell floor goal protein into shut proximity with a floor E3 ligase enzyme, leading to extremely selective and deep inhibition of illness pathways in affected tissues.
“Its proprietary Floor Removing Focusing on Chimeras (SureTACs) platform generates bispecific antibodies that pair the optimum E3 ligase with a disease-causing goal protein to stimulate its ubiquitination and lysosomal degradation with a excessive diploma of specificity. Laigo’s platform permits the event of first-in-class, dual-targeted therapies that eradicate disease-driving membrane targets,” the corporate defined.
Laigo notes that degrading the goal protein leads to simpler inhibition of illness pathways in comparison with typical therapeutics, whereas defending wholesome tissue and decreasing negative effects.
With the recent capital, the corporate plans to speed up the event of its SureTACs oncology programmes in the direction of the clinic, in addition to advance its three candidate programmes for chosen autoimmune and immunology indications and graft rejection.
Laigo is supported by a syndicate of outstanding worldwide buyers, resembling Kurma Companions, Biovance Capital, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Area, and Most cancers Analysis Horizons.
